Assassin’s Creed Mirage, the 13th installment in Ubisoft’s popular franchise, is set to be released on October 5th, a week earlier than originally planned. To help players determine when they can start playing, Ubisoft has provided global release times for both PC and console. In general, the game will be available in the early hours of October 5th, with some regions getting a head start on PC late in the evening of October 4th. Pre-loading is already available for Mirage.

For instance, in Los Angeles, the game will be playable on PC starting at 10 p.m. PDT on October 4th, while console players can start at midnight PDT on October 5th. Similar release times apply to other regions such as Montreal, London, Stockholm, Kyiv, Mexico City, Sao Paulo, New York, Paris, Abu Dhabi, Johannesburg, Shanghai, Tokyo, Seoul, and Sydney. It’s worth noting that Assassin’s Creed Mirage will also be released on the iPhone 15 and iPhone 15 Max Pro in the first half of 2024, although the exact release date is yet to be announced.

As the release date approaches, Ubisoft has urged fans to avoid sharing spoilers. Mirage follows the character Basim Ibn Ishaq, who was introduced in Assassin’s Creed Valhalla, and promises a return to the series’ roots with an emphasis on stealth and linear storytelling. To learn more about the game, players can check out hands-on previews and interviews with Narrative Director Sarah Beaulieu. The successful early release of Assassin’s Creed Mirage marks an exciting moment for fans of the franchise eagerly awaiting the next installment.

Source link

US FDA Gives Green Light to Pfizer’s Drug for Inflammatory Bowel Disease

Date:

The U.S. Food and Drug Administration (FDA) has granted approval to Pfizer’s drug Velsipity for the treatment of ulcerative colitis, an inflammatory bowel disease. This decision was based on data from a late-stage study, which demonstrated a reduction in disease symptoms when compared to a placebo. Velsipity, acquired by Pfizer in a $6.7 billion deal with Arena Pharmaceuticals last year, is expected to compete with Bristol Myers Squibb’s Zeposia, another approved treatment for ulcerative colitis. Despite being priced lower than Zeposia, Velsipity offers the advantage of not requiring patients to undergo laboratory testing before initiating treatment. Analysts estimate that Pfizer’s drug could generate $2.2 billion in sales by 2030 in a global market worth approximately $20 billion.

Ulcerative colitis is a condition characterized by ulcers in the digestive tract, leading to symptoms such as abdominal pain, bloody stools, and incontinence. It affects around 1.25 million individuals in the United States. The approval of Velsipity provides an additional treatment option for adults with ulcerative colitis and has the potential to make a significant impact on the market for inflammatory bowel disease medications. Pfizer’s acquisition of Velsipity as part of its deal with Arena Pharmaceuticals underscores the company’s commitment to expanding its portfolio and addressing the needs of patients with various medical conditions.

This development is a positive step forward in the management of ulcerative colitis, as it offers patients an alternative treatment option that has been deemed safe and effective by the FDA. The approval of Velsipity can potentially improve the quality of life for individuals living with ulcerative colitis by alleviating their symptoms and reducing the need for other forms of therapy. Additionally, the competitive pricing of Velsipity compared to similar treatments on the market may improve accessibility and affordability for patients. Pfizer’s entry into the ulcerative colitis market is expected to contribute to the growth of the company and pave the way for further advancements in the field of inflammatory bowel disease treatment.

Source link

DMN8 Partners
DMN8 Partnershttps://salvonow.com/
DMN8 Partners utilizes a strategy of Cross Channel marketing including local search engine optimization, PPC, messaging and hyper-targeted audiences allow our clients to experience results and ROI that fuel growth and expansion in their operations. There are a lot of digital marketing options across the country but partnering with an agency that understands multiple touches on multiple platforms allows your company’s message to be seen at the perfect time, on the perfect platform, by your perfect prospect. DMN8 Partners has had years of experience growing businesses. Start growing your business today and begin DOMINATE-ing your market.

More like this
Related

Unilever Dismisses Chief Schumacher, Elevates Finance Head Fernandez

The Editor's Digest offers complimentary access, curated weekly by...

Can AI Serve as Your Lawyer?

An Australian driver is facing accusations of illegally using...

ProPublica Enhances Native American Repatriation Database

In the previous year, significant progress was made by...

Fatal Accident Reported at Fortuna Mining’s Séguéla Mine, Côte d’Ivoire

Fortuna Mining, a Canadian company specializing in precious metals,...